|
Synonyms: DCR-PHXC | NN-7022 | Rivfloza®
nedosiran is an approved drug (FDA (2023))
Compound class:
Nucleic acid
Comment: Nedosiran (DCR-PHXC) is a synthetic double-stranded siRNA drug. It contains a target-selective guide strand, plus a passenger strand that is attached to an extended nucleotide region that acts as a dicer substrate siRNA which is conjugated with four N-acetylgalactosamine (GalNAc) sugars. These modifications act to both stabilise the siRNA and optimise orientation for presentation to hepatocytes [2,4]. Nedosiran targets lactate dehydrogenase A (LDHA) mRNA as a mecahnism to reduce urinary oxalate levels as a treatment for primary hyperoxaluria.
We have been unable to locate a full chemical SMILES for the drug, or its HELM notation. |
Classification  |
|
| Compound class | Nucleic acid |
| Compound subclass | siRNA |
| Target | lactate dehydrogenase A (LDHA) mRNA |
| Approved drug? | Yes. FDA (2023) |
| International Nonproprietary Names |
|
| INN number | INN |
| 11373 | nedosiran |
| Synonyms |
| DCR-PHXC | NN-7022 | Rivfloza® |
| Database Links |
|
| CAS Registry No. | 2266591-83-5 (source: WHO INN record) |
| ChEMBL Ligand | CHEMBL4594338 |
| DrugBank Ligand | DB17635 |
| GtoPdb PubChem SID | 504705434 |
| Search PubMed clinical trials | nedosiran |
| Search PubMed titles | nedosiran |
| Search PubMed titles/abstracts | nedosiran |
